<!DOCTYPE html>

<!-- paulirish.com/2008/conditional-stylesheets-vs-css-hacks-answer-neither/ -->
<!--[if lt IE 7]> <html class="no-js lt-ie9 lt-ie8 lt-ie7" lang="en"> <![endif]-->
<!--[if IE 7]>    <html class="no-js lt-ie9 lt-ie8" lang="en"> <![endif]-->
<!--[if IE 8]>    <html class="no-js lt-ie9" lang="en"> <![endif]-->
<!--[if gt IE 8]><!--> <html class="no-js" lang="en"> <!--<![endif]-->
<head>
	<meta charset="utf-8" />

	<!-- Set the viewport width to device width for mobile -->
	<meta name="viewport" content="width=device-width" />

	<title>PracticeUpdate : Story of the week</title>

	<!-- Included CSS Files -->
<!-- FontDeck
<link rel="stylesheet" href="http://f.fontdeck.com/s/css/l4MsFun30OJhB9DTDGcb8JQSAOQ/practicenetwork-foundation/22889.css" type="text/css" />
-->

	<link rel="stylesheet" href="assets/css/app.css">
	<link rel="stylesheet" href="assets/css/font-awesome.css">
	<link rel="stylesheet" href="assets/css/fc-webicons.css">
	<link rel="stylesheet" href="assets/css/foundation-icons-general.css">

	<script src="assets/js/foundation/modernizr.foundation.js"></script>

	<!-- IE Fix for HTML5 Tags -->
    <!--[if lt IE 9]>
        <script src="http://html5shiv.googlecode.com/svn/trunk/html5.js"></script>
    <![endif]-->

</head>
	<body id="page" class="update off-canvas slide-nav featured logged-out">
  <div class="widget ad">
    <div id="leaderboard" class="Breast ad-container">
      <div class="ad-title"><span class="ad-title-text">advertisement</span></div><!--/.ad-title-->
      <div id="leaderboardcontent" class="ad-content">
			</div><!--.ad-content-->
		</div><!--/#leaderboard.ad-container-->
  </div><!--/.widget.ad-->
	<div class="page-header">
	</div><!--/.page-header-->
	<div class="page-content">
	<section role="main">

<div class="single-item-container">
<div class="prompt access-prompt active-access">
	<!-- <a class="close"><i class="icon-remove"></i></a> -->
  <div class="prompt-header access-prompt-header">
		<span class="prompt-header-text"><i class="icon-time"></i> Available until <time datetime="13-07-06">July 6, 2013</time></hspan>
	</div><!--/.prompt-header-->
	<div class="prompt-body access-prompt-body">
  	<p>You're enjoying temporary access to this content because it was shared by a registered user. <a href="http://www.practiceupdate.com/User/Register">Create a free account</a> to gain permanent access to all PracticeUpdate content.</p>
	</div><!--/.prompt-body-->
	<div class="prompt-footer access-prompt-footer">
<a class="button small" href="http://www.practiceupdate.com/User/Register">Register Now</a>
	</div><!--/.prompt-footer-->
</div><!--/.prompt-->

<div class="prompt access-prompt expired-access">
	<!-- <a class="close"><i class="icon-remove"></i></a> -->
  <div class="prompt-header access-prompt-header">
		<span class="prompt-header-text"><i class="icon-time"></i> Access expired on <time datetime="13-07-06">July 6, 2013</time></hspan>
	</div><!--/.prompt-header-->
	<div class="prompt-body access-prompt-body">
  	<p>This content was originally shared by a registered user, but access has expired. <a href="http://www.practiceupdate.com/User/Register">Create a free account</a> to gain permanent access to all PracticeUpdate content.</p>
	</div><!--/.prompt-body-->
	<div class="prompt-footer access-prompt-footer">
<a class="button small" href="http://www.practiceupdate.com/User/Register">Register Now</a>
	</div><!--/.prompt-footer-->
</div><!--/.prompt-->

	<article class="type-blog featured single-item">
		<div class="item-header-container">
			<header class="item-header">
				<div class="flag-container"><span class="flag featured"><i class="icon-bolt"></i> featured</span></div>
				<div class="meta pub-meta">
					<span class="item-type">My Approach</span>
					<span class="item-pub-date"><time datetime="12-12-05">December 05, 2012</span>
				</div>
				<hgroup class="item-title-container">
					<h1 class="item-title">Second-Line FOLFIRI/Aflibercept Ups Survival in Metastatic Colorectal Cancer</h1>
					<p class="item-citation">{{source.citation}}</p>
				</hgroup><!-- /.item-title-container -->

		<div class="action-bar" style="padding-bottom:17px;">
			<div class="socialshare-actions">
					<span class='ss_facebook'><i class="icon-facebook-sign"></i></span>
					<span class='ss_twitter'><i class="icon-twitter-sign"></i></span>
					<span class='ss_googleplus'><i class="icon-google-plus-sign"></i></span>
					<span class='ss_linkedin'><i class="icon-linkedin-sign"></i></span>
					<span class='ss_email'><i class="icon-envelope-alt"></i></span>
					<span class='ss_print'><i class="icon-print"></i></span>
			</div><!--/.ssocialshare-actions-->
		</div><!--/.action-bar-->

			</header>
		</div><!--/.item-header-container-->
	<div class="item-content-container">
	<div class="item-content">
		<div class="item-content-section">
			<section class=" take-home-message">
				<h2>TAKE-HOME MESSAGE</h2>
					<div class="source-container">
						<div class="vcard">
						<div class="expert-photo">
							<!-- <img class="photo" src="content/img/users/Axel_Grothey_2009_REVISED_tcm8-199717.jpg"> -->
							<!-- <p class="label">Fellow</p> -->
						</div>

						<div class="expert-name">
							<!-- Axel  Grothey MD -->
							<!-- <p class="label">Fellow</p> --> Written by
							<a class="fn" href="#">
								<span class="n">
									<!-- <span class="honorific-prefix">Dr.</span> -->
									<span class="given-name">Patrick</span>
									<abbr class="additional-name"></abbr>
									<span class="family-name">Morris</span>,
									<span class="honorific-suffix">MD</span>
								</span>
							</a><!--/.fn-->
						</div><!--/.expert-name-->
						</div><!--/.vcard-->
					</div><!--/.source-container-->
				<p>In a phase III trial, patients with metastatic colorectal cancer who failed first-line oxaliplatin-based therapy had improved survival with second-line FOLFIRI plus the antiangiogenic agent aflibercept, compared with second-line FOLFIRI alone.</p>
			</section><!--/.take-home-message-->
		</div><!--/.item-content-section-->
		<div class="item-content-section">
			<section class="commentary">
				<div class="commentary-container">
					<h2>Expert Commentary</h2>
					<div class="source-container">
						<div class="vcard">
						<div class="expert-photo">
							<img class="photo" src="content/img/users/Axel_Grothey_2009_REVISED_tcm8-199717.jpg">
							<!-- <p class="label">Expert</p> -->
						</div>

						<div class="expert-name">
							<!-- Axel  Grothey MD -->
							<a class="fn" href="#">
								<span class="n">
									<!-- <span class="honorific-prefix">Dr.</span> -->
									<span class="given-name">Axel</span>
									<abbr class="additional-name"></abbr>
									<span class="family-name">Grothey</span>
									<span class="honorific-suffix">MD</span>
								</span>
							</a><!--/.fn-->
						</div><!--/.expert-name-->
						</div><!--/.vcard-->
					</div><!--/.source-container-->
						<p>Metastatic colorectal cancer is generally treated initially with a regimen of fluorouracil and leucovorin plus either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI). Patients cross over to the alternate regimen for second-line therapy. The antiangiogenic agent bevacizumab has been shown to increase survival in patients with metastatic colorectal cancer in the first-line setting when added to FOLFIRI and in the second-line setting when added to FOLFOX, but no biologic agent has been shown to improve survival in the second-line setting when added to FOLFIRI.</p><p>Aflibercept is a recombinant fusion protein that targets three factors that contribute to tumor angiogenesis: vascular endothelial growth factor A (VEGFA), VEGFB, and placental growth factor (PlGF). In a multinational phase III study sponsored by Sanofi, Van Cutsem et al added aflibercept to FOLFIRI as second-line therapy for metastatic colorectal cancer previously treated with oxaliplatin. Prior bevacizumab was allowed, but not prior irinotecan.</p><p>Between 2007 and 2010, a total of 1226 patients were randomized to receive aflibercept 4 mg/kg (n = 612) or placebo (n = 614) on day 1 every 2 weeks, followed by the FOLFIRI regimen (irinotecan 180 mg/m2, leucovorin 400 mg/m2, and fluorouracil 400 mg/m2 bolus and then 2400 mg/m2 by continuous infusion). Crossover to aflibercept after progression on placebo was not permitted.</p><p>At the February 2011 cutoff date for analysis of overall survival (OS), the primary endpoint, median follow-up was 22.28 months. The patients receiving aflibercept/FOLFIRI had a median survival of 13.50 months compared with 12.06 months for the placebo/FOLFIRI control patients (hazard ratio [HR], 0.817; P = .0032). At 2 years, survival rates were 28.0% and 18.7%, respectively. The treatment effect favoring aflibercept held in analyses of prespecified subgroups based on prior bevacizumab use and various patient characteristics at baseline.</p><p>Progression-free survival (PFS) increased from 4.7 months for controls to 6.9 months with use of aflibercept (HR, 0.758; P &lt; .0001). Subgroup analyses showed a consistent trend in PFS in favor of aflibercept. The response rate in patients with measurable disease was significantly higher with aflibercept vs placebo (19.8% vs 11.1%; P &lt; .001).</p><p>Grade 3 and 4 adverse events were more common with aflibercept than placebo (83.5% vs 62.5%, respectively). Toxicities related to anti-VEGF treatment were consistent with those reported in previous studies. Interestingly, some common adverse events related to treatment with FOLFIRI were more frequent in the aflibercept arm. These included grade 3 and 4 diarrhea, asthenia, stomatitis, infections, and palmar&#8211;plantar erythrodysesthesia, as well as grade 3 and 4 neutropenia, thrombocytopenia, and neutropenic complications.</p><p>The addition of aflibercept to FOLFIRI led to a relative reduction in the risk of death of 18.3%, compared with placebo/FOLFIRI. The early and continued divergence of the survival curves further supports the clinical value of the aflibercept results. Survival rates for aflibercept vs placebo were 38.5% vs 30.9% at 18 months, 28.0% vs 18.7% at 24 months, and 22.3% vs 12.0% at 30 months.</p><p>The authors concluded that aflibercept plus FOLFIRI may be a new therapeutic option for the treatment of metastatic colorectal cancer patients whose disease has progressed while on or after completion of an oxaliplatin-based regimen.</p>
				</div><!--/.commentary-container-->
			</section><!-- /.commentary-->
		</div><!-- ./item-content-section -->
<hr/>
<div class="item-content-section">
	<section class="abstract">
		<h2 class="content-section-header">summary</h2>
		<h3><h3>background</h3>
		<p>Patients with facial port-wine stains (PWS) often demonstrate oral manifestations of their disorder; however, the spectrum and prevalence of such findings among a cohort of patients with PWS has not been established. As a result, dermatologists and oral health specialists may be uncertain how to counsel their patients with PWS regarding oral hypervascularity, bony oral changes, and oral hygiene.</p>
		<h3>objectives</h3>
		<p>We sought to identify physical findings and complications involving the teeth, oral cavity, and perioral structures in individuals with facial PWS.</p>
		<h3>methods</h3>
		<p>This was a cross-sectional study of 30 patients with facial PWS. Descriptive data were collected through anonymous paired surveys completed by patients and their dentists, and analyzed (Fisher exact test) for trends based on physical findings and stage of the PWS.</p>
		<h3>results</h3>
		<p>The most common orodental manifestations according to patients were enlargement of the lip (53.3%), stained gums (46.7%), abnormal bite (30%), and spontaneous bleeding of the gums (26.7%). Staining of the gingiva correlated significantly with gingival hyperplasia (P = .006), maxillary hyperplasia (P = .014), and widened interdental spaces (P = .002), and in all cases gingival staining predated these findings. Lip hyperplasia was reported more frequently by patients than by their dentists (50% vs 18.2%, P = .008). Orodental manifestations were more common among patients with darker and thicker PWS. Hemorrhage after dental procedures was rare (4.5%).</p>
		</h3>LIMITATIONS:</h3>
		<p>Modest sample size and difficulty recruiting control subjects are limitations.</p>
		<h3>conclusions</h3>
		<p>Facial PWS commonly affect the orodental structures, and intraoral staining may predict future complications.</p>
	</section><!--/.abstract-->
</div><!--/.item-content-section-->
		</div><!--/.item-content-->
	</div><!--/.item-content-container-->
	<div class="item-source-container">
								<div class="item-source">
									<div class="vcard">
									<!-- <div class="journal-photo">
										<img class="photo" src="content/img/journal/jco.gif">
									</div> -->
									<div class="journal">

										<!--     -->
										<a class="fn" href="#">
											<span class="n">
												<!-- <span class="honorific-prefix">Dr.</span> -->
												<span class="given-name">Journal of Clinical Oncology</span>
											</span>
										</a><!--/.fn-->
									<h6 class="item-title">Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer</h6>
									<cite class="subheader">Clin Cancer Res. 2012 Mar 29;[Epub Ahead of Print], DN Finegold, CJ Baty, KZ Knickelbein, S Perschke, SE Noon, D Campbell, JM Karlsson, D Huang, MA Kimak, EC Lawrence, E Feingold, SD Meriney, AM Brufsky, RE Ferrell</cite>
									</div>
									<!--/.journal-->
<!--/.journal-->
									</div><!--/.vcard-->
								</div><!--/.item-source -->
								<div class="user-actions">
									<!-- Abstract only -->
									<div class="publisher-access">
										<div class="panel abstract">
											<p>The publisher has made this abstract available for free.</p>
											<a href="#" class="button">Access this abstract now</a>
										</div><!--/.panel-->
									</div><!-- /.publisher-access -->

									<!-- Article Free for 30 days -->
									<div class="publisher-access">
										<div class="panel free-thirty">
											<p>The publisher has made this article available for free until {{free-end-date}}.</p>
											<a href="#" class="button">Access this article now</a>
										</div><!--/.panel-->
									</div><!-- /.publisher-access -->

									<!-- Article free -->
									<div class="publisher-access">
										<div class="panel free">
											<p>The publisher has made this abstract available for free.</p>
											<a href="#" class="button">Access this article now</a>
										</div><!--/.panel-->
									</div><!-- /.publisher-access -->

								</div><!-- /.user-actions -->
	</div><!--/.item-source-container-->

<footer class="copyright item-footer">
<p>Copyright &copy; Elsevier Inc. All rights reserved.</p>
</footer>
</div><!--/.item-container-->
				<div class="recommended">
					<div class="widget recent">
					</div><!--/.recent-->
					<div class="widget ad">
						<img src="http://placehold.it/300x250" align="ad" title="ad" />
					</div>
				</div><!--/.recommended-->

	</section><!--/[role="main"]-->
	<section id="sidebar" role="complementary">
		<div class="dashboard">
			<div class="component user-console">
			</div><!--/.component.user-console-->

			<div class="component user-topic">
			</div><!--/.component.user-topic-->
<!-- 			<div class="component user-topics">
				<nav role="navigation">
					<ul class="side-nav">
						<li class="nav-header">My Topics
							<a href="#" ><i class="icon-cog"></i></a>
						</li>
						<li class="active"><a href="#">All</a></li>
						<li><a href="#">Hemotology</a></li>
						<li><a href="#">Urology</a></li>
					</ul>
				</nav>
			</div> --><!--/.component.user-topics-->
<!-- 			<div class="component user-lists">
				<nav role="navigation">
					<ul class="side-nav">
						<li class="nav-header">My Lists<a href="#" ><i class="icon-cog"></i></a></li>
					<li><a href="#">Custom List #1</a></li>
					<li><a href="#">Custom List #2</a></li>
					<li><a href="#">Custom List #3</a></li>
					</ul>
				</nav>
			</div> --><!--/.component.user-lists-->
			<div class="component topic-spotlight">
				<nav role="navigation">
					<ul class="side-nav">
						<li class="nav-header">Topic Spotlight
						<li><a href="#">Breast ER-Positive</a></li>
					</ul>
				</nav>
			</div><!--/.component.user-topic-->
			<div class="panel">
				<img src="http://placehold.it/200x200" /><p><!-- Meet Our Experts --> Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.<p>
			</div>
		</div><!--/.sidebar-->
	</section><!--/.[role="complimentary"]-->
</div><!--/.page-content-->
	<footer class="page-footer">
	</footer><!-- /.page-footer -->

	<!-- Included JS Files (Uncompressed) -->
  <script src="assets/js/foundation/jquery.js"></script>

	<script src="assets/js/foundation/jquery.foundation.accordion.js"></script>
	<script src="assets/js/foundation/jquery.foundation.alerts.js"></script>
	<script src="assets/js/foundation/jquery.foundation.buttons.js"></script>
	<script src="assets/js/foundation/jquery.foundation.forms.js"></script>
	<script src="assets/js/foundation/jquery.foundation.mediaQueryToggle.js"></script>
	<script src="assets/js/foundation/jquery.foundation.navigation.js"></script>
	<script src="assets/js/foundation/jquery.foundation.orbit.js"></script>
	<script src="assets/js/foundation/jquery.foundation.reveal.js"></script>
	<script src="assets/js/foundation/jquery.foundation.tabs.js"></script>
	<script src="assets/js/foundation/jquery.foundation.tooltips.js"></script>
	<script src="assets/js/foundation/jquery.placeholder.js"></script>


	<script src="assets/js/foundation/app.js"></script>
	<script src="assets/js/foundation/dev-app.js"></script>
	<script src="assets/js/foundation/jquery.offcanvas.js"></script>

	<script src="assets/js/mustache.js"></script>

	<!-- Mustache - homepage feed template -->
	<script>
	<!-- Mustache - homepage feed template -->
	$.getJSON('content/json/feed.json', function(data) {
		$.get('assets/mustache/feed-item.mustache', function(template) {
			//alert('Load was performed.');
	    var html = Mustache.to_html(template, data);
	    $('.stream-container').html(html);
		});

	});

	<!-- Mustache - homepage recent template -->
	$.getJSON('content/json/recent.json', function(data) {
		$.get('assets/mustache/recent.mustache', function(template) {
			//alert('Load was performed.');
	    var html = Mustache.to_html(template, data);
	    $('.recent').html(html);
		});

	});

	<!-- Mustache - homepage user-console template -->
	$.get('assets/mustache/user-console.mustache', function(template) {
		//alert('Load was performed.');
    var html = Mustache.to_html(template);
    $('.user-console').html(html);
	});

		<!-- Mustache - homepage user-topic template -->
	$.get('assets/mustache/user-topic.mustache', function(template) {
		//alert('Load was performed.');
    var html = Mustache.to_html(template);
    $('.user-topic').html(html);
	});

	</script>

</body>
</html>